MPCs for Generation of New Blood Vessels—heart failure, coronary artery disease . The Company is in the process of forming relationships with diverse corporate partners to enable rapid penetration in each market by product and geography. The Company envisages that for patients with acute myocardial infarction, congestive heart failure, and coronary artery disease, the MPCs will be injected by cardiac catheter or minimally-invasive devices directly into the heart.

MPCs for Regeneration and Healing of Heart Muscle and Skin Ulcers . For patients in need of heart muscle repair, alone or as adjunct to coronary artery bypass grafting (CABG), or for patients in need of healing of skin ulcers, the MPC need to be delivered together with a biodegradable patch or matrix. For these applications, the Company has been in discussions with corporate partners with expertise in scaffold technology.

SDF-1 and PAI-1 Inhibitor Stent Development Programs . The Company will develop a series of drug-eluting stents for both coronary and peripheral artery angioplasty procedures. It is anticipated that clinical development, marketing, and distribution of these technologies will be performed in conjunction with device companies dominant in these fields and with appropriate distribution networks.